Evidence map›Paper›PMID 40958880›Full record

ReviewFrontiers in oncology2025

Potential application of nanodelivery systems targeting ELAVL1 in prostate cancer treatment.

Shasha Min, Mengmeng Guo, Jianuo Du, Jiaohuang Chen, Yanting Shen, Fuwen Yuan, Zhong Wang, Zhonglin Cai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shasha Min *School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Mengmeng Guo *Department of Urology and Andrology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China.
Jianuo DuSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Jiaohuang ChenSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Yanting ShenSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Fuwen YuanSchool of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhong WangSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.
Zhonglin CaiSchool of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prostate cancer (PCa) is one of the most common malignant tumors in men, with increasing incidence and mortality rates, and its treatment still faces many challenges and unmet needs. ELAVL1 (human antigen R, HuR) is an RNA-binding protein that plays a crucial role in the development and progression of various cancers. Studies have shown that ELAVL1 is highly expressed in PCa and that inhibiting its expression significantly reduces prostate cell proliferation and metastasis. However, the clinical application of ELAVL1-targeting therapies remains limited by the lack of effective delivery strategies. In this context, recent advances in nanodelivery systems offer promising solutions, providing both enhanced targeting efficiency and insights for future prostate cancer treatment strategies. Objective: This review aims to explore the potential of ELAVL1-targeted therapy based on nanodelivery systems in PCa, analyze its advantages and challenges, and provide insights into future research directions. Methods: A systematic review of recent literature summarizing the expression characteristics and biological functions of ELAVL1 in PCa was conducted. Additionally, the advantages, challenges, and applications of various nanomaterials in cancer therapy are discussed. Results: Nanodelivery systems have shown significant potential in the treatment of prostate cancer.

Indexed as

cancerELAVL1 (HuR)nanodelivery systemprostate cancersiRNA

Identifiers

PMID40958880
PMCPMC12433880

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.